Literature DB >> 14557372

Reversal of atrial mechanical dysfunction after cardioversion of atrial fibrillation: implications for the mechanisms of tachycardia-mediated atrial cardiomyopathy.

Prashanthan Sanders1, Joseph B Morton, Peter M Kistler, Jitendra K Vohra, Jonathan M Kalman, Paul B Sparks.   

Abstract

BACKGROUND: Atrial mechanical "stunning" develops after cardioversion of atrial fibrillation (AF) and is implicated in the genesis of thromboembolic complications. However, the mechanisms responsible for this phenomenon are poorly understood. Whether atrial mechanical dysfunction caused by AF can be reversed by pacing at increased rates or by pharmacological agents is unknown. METHODS AND
RESULTS: Twenty-six patients with AF undergoing cardioversion were dichotomized prospectively on the basis of the duration of arrhythmia as short-duration (1 to 6 months) or long-duration (> or =3 years) AF. Left atrial appendage emptying velocities (LAAEVs) and spontaneous echocardiographic contrast (LASEC) were assessed by transesophageal echocardiography during AF, after reversion to sinus rhythm, during atrial pacing at cycle lengths of 750 to 250 ms, after a postpacing pause, and with isoproterenol. In patients with short-duration AF, LAAEV decreased (42.0+/-2.7 to 18.5+/-2.0 cm/s; P<0.0001) and LASEC increased (0.9+/-0.3 to 2.2+/-0.3; P<0.01) with termination of AF; pacing increased LAAEV (48.3+/-4.1 cm/s; P<0.0001) and decreased LASEC (1.5+/-0.3; P<0.01); isoproterenol increased LAAEV (73.3+/-7.8 cm/s; P<0.0001) and decreased LASEC (0.3+/-0.2; P<0.01); and the postpacing pause increased LAAEV (68.3+/-3.8 cm/s; P<0.0001). In contrast, patients with long-duration AF demonstrated a significantly attenuated response of atrial mechanical function at each time point. With termination of AF, LAAEV decreased (19.1+/-2.6 to 8.2+/-1.0 cm/s; P=0.003) and LASEC increased (2.0+/-0.2 to 3.3+/-0.2; P<0.01); pacing increased LAAEV (18.4+/-2.7 cm/s; P<0.0001) and decreased LASEC (2.3+/-0.2; P<0.01); isoproterenol increased LAAEV (26.1+/-3.9 cm/s; P=NS to equivalent atrial rate) and decreased LASEC (1.0+/-0.3; P<0.01); and the postpacing pause increased LAAEV (27.2+/-2.4 cm/s; P=0.007).
CONCLUSIONS: Atrial pacing at increased rates and isoproterenol can reverse atrial mechanical stunning associated with short-duration AF. In contrast, long-duration AF is associated with an attenuated response to these maneuvers. These findings suggest a functional contractile apparatus in the mechanically remodeled atrium caused by AF; however, with longer durations of AF, additional factors may determine atrial mechanical function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14557372     DOI: 10.1161/01.CIR.0000091408.45747.04

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  14 in total

1.  Prospective validation of phased array intracardiac echocardiography for the assessment of atrial mechanical function during catheter ablation of atrial fibrillation.

Authors:  M Rotter; P Sanders; P Jaïs; M Hocini; Y Takahashi; L-F Hsu; F Sacher; T Rostock; M Haïssaguerre
Journal:  Heart       Date:  2006-03       Impact factor: 5.994

Review 2.  Structural and Functional Remodeling of the Left Atrium: Clinical and Therapeutic Implications for Atrial Fibrillation.

Authors:  Rajeev Pathak; Dennis H Lau; Rajiv Mahajan; Prashanthan Sanders
Journal:  J Atr Fibrillation       Date:  2013-12-31

Review 3.  Atrial Remodeling And Atrial Fibrillation: Mechanistic Interactions And Clinical Implications.

Authors:  Bandar Al Ghamdi; Walid Hassan
Journal:  J Atr Fibrillation       Date:  2009-06-01

4.  Atrial pacing failure following termination of atrial fibrillation by acute administration of disopyramide phosphate.

Authors:  Ryuko Anzawa; Shin-Ichiro Ishikawa; Yasuyuki Tanaka; Fumiko Okazaki; Seibu Mochizuki
Journal:  J Interv Card Electrophysiol       Date:  2005-06       Impact factor: 1.900

5.  Acute improvement of atrial mechanical stunning after electrical cardioversion of persistent atrial fibrillation: comparison between biatrial and single atrial pacing.

Authors:  M Takagi; A Doi; N Shirai; K Hirata; Y Takemoto; K Takeuchi; J Yoshikawa
Journal:  Heart       Date:  2005-01       Impact factor: 5.994

6.  Mitral annular velocity by Doppler tissue imaging for the evaluation of atrial stunning after cardioversion of atrial fibrillation.

Authors:  Abdullah Dogan; Omer Gedikli; Mehmet Ozaydin; Gurkan Acar; Alaettin Avsar; Ahmet Altinbas
Journal:  Int J Cardiovasc Imaging       Date:  2008-08-29       Impact factor: 2.357

7.  Short- and long-term associations of atrial fibrillation catheter ablation with left atrial structure and function: A cardiac magnetic resonance study.

Authors:  Mohammadali Habibi; Joao A C Lima; Esra Gucuk Ipek; David Spragg; Hiroshi Ashikaga; Joseph E Marine; Ronald D Berger; Hugh Calkins; Saman Nazarian
Journal:  J Cardiovasc Electrophysiol       Date:  2020-12-29

Review 8.  Rationale and current perspective for early rhythm control therapy in atrial fibrillation.

Authors:  Isabelle C Van Gelder; Laurent M Haegeli; Axel Brandes; Hein Heidbuchel; Etienne Aliot; Josef Kautzner; Lukasz Szumowski; Lluis Mont; John Morgan; Stephan Willems; Sakis Themistoclakis; Michele Gulizia; Arif Elvan; Marcelle D Smit; Paulus Kirchhof
Journal:  Europace       Date:  2011-07-22       Impact factor: 5.214

9.  Prediction of left atrial fibrosis with speckle tracking echocardiography in mitral valve disease: a comparative study with histopathology.

Authors:  Ae-Young Her; Eui-Young Choi; Chi Young Shim; Byoung Wook Song; Sak Lee; Jong-Won Ha; Se-Joong Rim; Ki Chul Hwang; Byung Chul Chang; Namsik Chung
Journal:  Korean Circ J       Date:  2012-05-24       Impact factor: 3.243

10.  Treatment patterns associated with stroke prevention in patients with atrial fibrillation in three major cities in the People's Republic of china.

Authors:  Bao Liu; Larry Z Liu; Jianwei Xuan; Man Luo; Yansheng Li; Chaohui Duan; Hongqin Cheng; Xiaohui Yang
Journal:  Int J Gen Med       Date:  2013-12-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.